HC Wainwright Reiterates “Neutral” Rating for Aclaris Therapeutics (NASDAQ:ACRS)

HC Wainwright reissued their neutral rating on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research report report published on Tuesday morning, Benzinga reports.

Separately, StockNews.com raised Aclaris Therapeutics from a sell rating to a hold rating in a report on Thursday, July 25th. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of Hold and an average target price of $23.00.

Aclaris Therapeutics Stock Up 3.4 %

ACRS stock opened at $1.21 on Tuesday. The firm has a market capitalization of $86.23 million, a PE ratio of -1.11 and a beta of 0.21. Aclaris Therapeutics has a twelve month low of $0.59 and a twelve month high of $7.47. The stock has a 50-day simple moving average of $1.24 and a two-hundred day simple moving average of $1.21.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. The business had revenue of $2.77 million during the quarter, compared to analyst estimates of $1.74 million. Aclaris Therapeutics had a negative return on equity of 53.18% and a negative net margin of 183.28%. On average, equities research analysts anticipate that Aclaris Therapeutics will post -0.65 EPS for the current fiscal year.

Insider Transactions at Aclaris Therapeutics

In other Aclaris Therapeutics news, major shareholder Braden Michael Leonard acquired 107,434 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was bought at an average price of $1.14 per share, with a total value of $122,474.76. Following the completion of the acquisition, the insider now owns 13,095,572 shares of the company’s stock, valued at $14,928,952.08. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders acquired 930,502 shares of company stock valued at $1,119,232. 6.40% of the stock is owned by corporate insiders.

Institutional Trading of Aclaris Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ACRS. Bain Capital Life Sciences Investors LLC boosted its stake in Aclaris Therapeutics by 2.9% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 3,500,000 shares of the biotechnology company’s stock worth $3,675,000 after buying an additional 100,000 shares in the last quarter. Octagon Capital Advisors LP bought a new stake in Aclaris Therapeutics in the fourth quarter valued at approximately $105,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Aclaris Therapeutics in the first quarter valued at approximately $39,000. BNP Paribas Financial Markets lifted its position in Aclaris Therapeutics by 10.9% in the first quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock valued at $299,000 after purchasing an additional 23,747 shares during the last quarter. Finally, Deuterium Capital Management LLC bought a new stake in Aclaris Therapeutics in the first quarter valued at approximately $99,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.